Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma

Stopped early · Phase 2/Phase 3

Conditions studied: Neuroblastoma

In brief

The goal of this clinical research study is to learn how long it takes for certain types of transplanted stem cells to produce new blood cells. The safety of this treatment will also be studied. Finally, researchers want to learn if collecting the cells with the CliniMACS device can decrease the possibility of tumor cells contaminating (appearing in) the stem cells that are reinfused into participants.

Key facts

Study ID

NCT00539500

Run by

M.D. Anderson Cancer Center

People needed

3

Starts

2007-10-01

Expected to finish

2012-09-05

Last updated by the study team

2019-07-26

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed high-risk Neuroblastoma defined as: a. INSS 2A/2B older then 365 days with MYCN amplified, unfavorable histology, and any ploidy. b. INSS Stage 3, older than 365 days with MYCN amplification and/or unfavorable histology. c. INSS Stage 4 or 4S, less than 365 days of age, with MYCN amplification d. INSS Stage 4, over 365, regardless of MYCN amplification or histology.
• Pre-transplant modalities may include surgery, chemotherapy, or radiation therapy. Radiation must not include lung fields. Only patients in complete response (CR), or partial response (PR) at the primary site will be eligible.
• Any recurrent neuroblastoma with at least a partial response to salvage therapy.
• Lansky performance score greater than or equal to 50 for patients </= 16 years of age, or Zubrod performance status score of 0-2 for patients > 16 years of age.
• No symptomatic pulmonary disease. forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and Carbon Monoxide Diffusing Capacity (DLCO) >/= 50% of expected corrected for hemoglobin. If unable to perform pulmonary function test (most children < 6 years of age), pulse oximetry >/= 92% on room air.
• Adequate cardiac function as demonstrated by left ventricular ejection fraction >/= 50% by echocardiogram.
• Adequate hepatic function as defined as serum glutamic-oxaloacetic transaminase, SGOT (AST) and serum glutamic-pyruvic transaminase, SGPT (ALT)< 5 times upper limits of normal.
• All patients and/or their parents or legal guardians must sign a written informed consent.
• Females of childbearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization must have a negative urine pregnancy test within 30 days of registering. Patients will be informed of the risk of not using adequate contraception.

You may not qualify if…

• Patient is pregnant or breast-feeding.
• Active infection not controlled by antibiotics after seven days of therapy.
• Brain metastases.

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.